World-First Immunotherapy Trial Aims to Reprogram Immune System in Type 1 Diabetes
• Australian researchers at The University of Queensland have dosed the first five participants in a groundbreaking clinical trial of ASITI-201, an immunotherapy designed to rebalance immune response in Type 1 diabetes.
• The novel treatment combines pancreatic protein fragments with vitamin D to prevent immune attacks on insulin-producing cells, potentially preserving pancreatic function and reducing insulin dependence in recently diagnosed patients.
• If successful, the therapy could fundamentally change treatment approaches by addressing the root cause of Type 1 diabetes, with future applications potentially including prevention in high-risk individuals and adaptation for other autoimmune conditions.
Nivolumab/Relatlimab Combination Demonstrates Sustained Overall Survival Benefit in Advanced Melanoma
• Extended analysis of the RELATIVITY-047 trial shows nivolumab/relatlimab significantly improves overall survival compared to nivolumab alone in advanced melanoma patients.
• Median overall survival reached 51.0 months with the combination therapy versus 34.1 months with nivolumab monotherapy, indicating a substantial survival advantage.
• The study also reported improved progression-free survival and melanoma-specific survival with the nivolumab/relatlimab combination.
• No new safety signals were identified, reinforcing the combination's manageable safety profile in previously untreated advanced melanoma.
BellaSeno Initiates Clinical Trials for Resorbable Breast and Chest Implants
BellaSeno GmbH has launched two clinical trials in Australia for its resorbable implants aimed at treating pectus excavatum and for breast implant revision or congenital defect correction. The trials involve porous polycaprolactone implants that are absorbed by the body over time, leaving behind natural tissue.
© Copyright 2025. All Rights Reserved by MedPath